AIDS (London, England) · 2025
Pubertal onset in children with in-utero HIV/antiretroviral exposure in Botswana.
СтатьяНаблюдательное исследованиеResearch Support, N.I.H., IntramuralПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Jao Jennifer, Gochanour Caroline, Williams Paige L, Schenkel Sara, Kgole Samuel, Masasa Gosego, Phale Boitshepo, Kgathi Coulson, Makhema Joseph, Ralegoreng Thuto, Masheto Gaerolwe, Shaw Natalie D, Serghides Lena, Shapiro Roger, Lockman Shahin, Powis Kathleen M
Аннотация
OBJECTIVE: We assessed whether children/adolescents ages 9-11 years with in-utero HIV exposure but uninfected (CAHEU) had a lower chance of pubertal onset compared to children/adolescents who were HIV-unexposed (CAHU) during gestation. Among CAHEU, we assessed the association of in-utero combination antiretroviral therapy (ART) vs. zidovudine monotherapy exposure with pubertal onset.
DESIGN: An observational cross-sectional study.
METHODS: Pubertal onset (Tanner stage ≥2) was classified by sex and by in-utero HIV exposure status for each puberty indicator (pubic hair, breast development in girls, and male genitalia in boys) among adolescents aged 9-11 years from the Botswana-based FLOURISH study. Logistic regression models were fit to assess the association of in-utero HIV/ARV exposure with pubertal onset, adjusting for age at assessment and potential confounders. Among CAHEU, we compared the occurrence of pubertal onset for ART-exposed vs. zidovudine-exposed.
RESULTS: We evaluated 325 children/adolescents (228 CAHEU) at median age (IQR) 10.0 years (9.5, 10.6 years). CAHEU had lower mean BMI Z -scores at Tanner assessment (-0.36 vs. 0.19) than CAHU. While female CAHEU had higher odds of pubertal onset by pubic hair compared with female CAHU (adjusted odds ratio=2.75, 95% confidence interval: 1.04-7.30), no other differences in pubertal onset were observed by in-utero HIV exposure. Among CAHEU, no differences in pubertal onset by in-utero exposure to ART vs. zidovudine were observed.
CONCLUSION: In this small Botswana cohort, we observed no consistent differences in pubertal onset by in-utero HIV exposure status or by in-utero antiretroviral exposure. Longitudinal studies are needed to confirm these findings.
DESIGN: An observational cross-sectional study.
METHODS: Pubertal onset (Tanner stage ≥2) was classified by sex and by in-utero HIV exposure status for each puberty indicator (pubic hair, breast development in girls, and male genitalia in boys) among adolescents aged 9-11 years from the Botswana-based FLOURISH study. Logistic regression models were fit to assess the association of in-utero HIV/ARV exposure with pubertal onset, adjusting for age at assessment and potential confounders. Among CAHEU, we compared the occurrence of pubertal onset for ART-exposed vs. zidovudine-exposed.
RESULTS: We evaluated 325 children/adolescents (228 CAHEU) at median age (IQR) 10.0 years (9.5, 10.6 years). CAHEU had lower mean BMI Z -scores at Tanner assessment (-0.36 vs. 0.19) than CAHU. While female CAHEU had higher odds of pubertal onset by pubic hair compared with female CAHU (adjusted odds ratio=2.75, 95% confidence interval: 1.04-7.30), no other differences in pubertal onset were observed by in-utero HIV exposure. Among CAHEU, no differences in pubertal onset by in-utero exposure to ART vs. zidovudine were observed.
CONCLUSION: In this small Botswana cohort, we observed no consistent differences in pubertal onset by in-utero HIV exposure status or by in-utero antiretroviral exposure. Longitudinal studies are needed to confirm these findings.